DYAI - Dyadic International, Inc.
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.1700 |
| Open | 2.1600 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 2200 |
| Day's Range | 2.1600 - 2.2600 |
| 52 Week Range | 1.1200 - 3.5600 |
| Volume | |
| Avg. Volume | 38,930 |
| Market Cap | 62.808M |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2800 |
| Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Related Research
GlobeNewswireDyadic to Participate at Upcoming Events in June
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participa
Simply Wall St.Dyadic International (NASDAQ:DYAI) shareholders are up 12% this past week, but still in the red over the last three years
While not a mind-blowing move, it is good to see that the Dyadic International, Inc. ( NASDAQ:DYAI ) share price has...
Zacks Small Cap ResearchDYAI: Abundant Opportunities in Products and Animal & Human Health
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT First Quarter 2023 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) provided 2022 operational and financial results in a press release on May 10, 2023, filed its Form 10-Q with the SEC and held a conference call with investors. Dyadic announced several new collaborations and expanded agreements
- GlobeNewswire
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop, manufacture and commercialize affordable vaccines and biologics for human and animal health for African ContinentExpanded collaboration with Phibro/Abic animal health to develop vaccines for animal diseasesFully funded co-development and marketing agreement with Fermbox to use Dapibus™ platform to develop a
- GlobeNewswire
Dyadic to Participate at Two Industry Events in May
JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that they will be participating in the following events during the month of May. PEGS Boston Conf
- GlobeNewswire
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
JUPITER, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a co-development and marketing a
- GlobeNewswire
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a
- GlobeNewswire
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a Notice of Allowance from
- GlobeNewswire
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
JUPITER, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced it signed an expanded licensing agreement for its C1-cell
Insider MonkeyDyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Good evening, and welcome to Dyadic International’s Fiscal Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management’s prepared remarks, there will be a brief question-and-answer session. As a reminder, this conference is being recorded today, […]
- Simply Wall St.
Dyadic International Full Year 2022 Earnings: Revenues Disappoint
Dyadic International ( NASDAQ:DYAI ) Full Year 2022 Results Key Financial Results Revenue: US$2.93m (up 22% from FY...
- Zacks Small Cap Research
DYAI: 2022 Results
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) provided 2022 operational and financial results in a press release on March 29, 2023, filed its Form 10-K with the SEC and held a conference call with investors. Dyadic has advanced to the next stage of a development company with C1 derived proteins evaluated in human subjects in the
- GlobeNewswire
Dyadic to Present at World Vaccine Congress Washington 2023
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccin
- GlobeNewswire
Dyadic Reports 2022 Year End Results and Recent Company Progress
Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate which has completed dosing of all patients in both the low and high dose testing groupsOngoing research and license agreements with Janssen, Hengrui, NIIMBL and others for the C1-expressed therapeutic proteins for human health Expanded collaboration with Phibro/Abi
- GlobeNewswire
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it will report its financial results for the year ended 2022 and host a corporate upda
- Simply Wall St.
Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 JUPITER, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction
- GlobeNewswire
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
JUPITER, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its management and business partners from VTT Technical Research Centre of Finland Ltd, wi
- GlobeNewswire
Dyadic to Participate in Two Upcoming Investor Conferences
JUPITER, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be participating in the following two upcom
- Zacks Small Cap Research
DYAI: First Patient Administered C1 Derived Vaccine
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) achieved a pivotal point in its maturation as a provider of therapeutic proteins as it and partner Rubic One Health dosed its first patient with DYAI-100, a COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate. This is an important milestone as
- GlobeNewswire
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced during management’s Q3 earnings call, it has initiated dosing in its Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the DYAI-100 COVID-19 recombinant protein re
- GlobeNewswire
Dyadic Announces Sale of Equity Interest in Alphazyme
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it received approximately $1.27 million in connection with the sale of its equity interest in Alphazyme LL
- GlobeNewswire
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA USAJUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effect
- GlobeNewswire
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s anticipated First-In-Human clinical trial designed to demonstrate clinical safety and immune response in humans for its DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidate.The C1-cell produced RBD-C-tag antigen strongly binds ACE2 receptors in vitro. Adjuvanted RBD-C-tag-based vaccine ca
Zacks Small Cap ResearchDYAI: DYAI-100 Phase I in the Spotlight
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Third Quarter 2022 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) provided third quarter 2022 operational and financial results in a press release on November 10, 2022, filed its Form 10-Q with the SEC and hosted a conference call with investors. Dyadic is more explicitly orienting its efforts